Top

Published in:

Open Access 01-08-2004 | Research article

Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies

Authors: Fabrizio Conti, Cristiano Alessandri, Daniela Bompane, Michele Bombardieri, Francesca Romana Spinelli, Anna Carlotta Rusconi, Guido Valesini

Published in: Arthritis Research & Therapy | Issue 4/2004

Abstract

This study was performed to determine the correlation between psychiatric manifestations and several autoantibodies that might participate in the pathogenesis of psychiatric disorders in the course of systemic lupus erythematosus (SLE). Fifty-one unselected outpatients with SLE were enrolled. Psychiatric evaluation was performed according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. The prevalence of antibodies against endothelial cells (AECA), cardiolipin, β2 glycoprotein I, Ro, Ro52, La, glial fibrillary acidic protein, ribosomal P protein, dsDNA, and nucleosomes was assessed by experimental and commercial enzyme-linked immunosorbent assays. According to the cutoff value, AECA were present in 11 of 17 (64.7%) SLE patients with psychosis and mood disorders and in 10 of 34 (29.4%) patients without psychiatric manifestations other than anxiety (P = 0.03). Moreover, the AECA binding index was significantly higher in the first group (P = 0.03). Conversely, no significant correlation was found between the presence of the other autoantibodies studied and psychiatric involvement. The results of this study suggest a relationship between AECA and psychosis and mood disorders in SLE, supporting the hypothesis of a biological origin of these disturbances.

Available only for authorised users

ACR ad hoc committee on Neuropsychiatric Lupus Nomenclature: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999, 42: 599-608. 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.CrossRef

Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, Auvinen A: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001, 45: 419-423. 10.1002/1529-0131(200110)45:5<419::AID-ART360>3.0.CO;2-X.CrossRefPubMed

Buchbinder R, Hall S, Littlejohn GO, Ryan PF: Neuropsychiatric manifestations of systemic lupus erythematosus. Aust N Z J Med. 1988, 18: 679-684.CrossRefPubMed

Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus. Medicine. 1968, 47: 337-369.CrossRefPubMed

Wekking EM: Psychiatric symptoms in systemic lupus erythematosus: an update. Psychosom Med. 1993, 55: 219-228.CrossRefPubMed

Iverson GL, McCracken LM: Attributing psychopathology to systemic lupus erythematosus: some methodological considerations. Ann Rheum Dis. 1992, 51: 134-135.PubMedCentralCrossRefPubMed

Lewis DA, Smith RE: Steroid induced psychiatric syndromes: a report of 14 cases and review of literature. J Affect Disord. 1983, 5: 319-332. 10.1016/0165-0327(83)90022-8.CrossRefPubMed

Hay EM, Black D, Huddy A, Creed F, Tomenson B, Bernstein RM, Holt PJ: Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 1992, 35: 411-416.CrossRefPubMed

Lindal E, Thorlacius S, Steinsson K, Stefansson JG: Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol. 1995, 24: 346-351.CrossRefPubMed

10.

Segui J, Ramos-Casals M, Garcia-Carrasco M, de Flores T, Cervera R, Valdes M, Font J, Ingelmo M: Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. Lupus. 2000, 9: 584-588. 10.1191/096120300678828730.CrossRefPubMed

11.

Shortall E, Isenberg D, Newman SP: Factors associated with mood and mood disorders in SLE. Lupus. 1995, 4: 272-279.CrossRefPubMed

12.

Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH: Autoantibodies in neuropsychiatric lupus. Autoimmunity. 2002, 35: 79-86. 10.1080/08916930290016547.CrossRefPubMed

13.

Bonfa E, Elkon KB: Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum. 1986, 29: 981-985.CrossRefPubMed

14.

Teh LS, Isenberg DA: Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum. 1994, 37: 307-315.CrossRefPubMed

15.

Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB: Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med. 1987, 317: 265-271.CrossRefPubMed

16.

Isshi K, Hirohata S: Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1996, 39: 1483-1490.CrossRefPubMed

17.

Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL: Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med. 1991, 90: 54-62. 10.1016/0002-9343(91)90506-S.CrossRefPubMed

18.

Teh LS, Bedwell AE, Isenberg DA, Gordon C, Emery P, Charles PJ, Harper M, Amos N, Williams BD: Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis. 1992, 51: 489-494.PubMedCentralCrossRefPubMed

19.

Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997, 40: 1725-CrossRefPubMed

20.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington, DC: American Psychiatric Association, 4

21.

First MB, Spitzer RL, Gibbon M, Williams JB: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/P), Computer Program Handbook. Version 2.0. 1996, New York: New York State Psychiatric Institute, Biometrics Research Department

22.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640.CrossRefPubMed

23.

Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A, Khamashta M, Hughes GR, Zanussi C, Balestrieri G: Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol. 1988, 74: 247-253.PubMedCentralPubMed

24.

van der Zee JM, Siegert CE, de Vreede TA, Daha MR, Breedveld FC: Characterization of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol. 1991, 84: 238-244.PubMedCentralPubMed

25.

Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590.CrossRef

26.

Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, Rhine CB, Padilla P, McGlasson D: Neuropsychiatric syndromes in lupus: prevalence using standardized definition. Neurology. 2002, 58: 1214-1220.CrossRefPubMed

27.

Mok CC, Lau CS, Wong RWS: Neuropsychiatric manifestations and their clinical associations in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol. 2001, 28: 766-771.PubMed

28.

Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A: The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001, 57: 496-500.CrossRefPubMed

29.

D'Cruz DP, Houssiau FA, Ramirez G, Baguley E, McCutcheon J, Vianna J, Haga HJ, Swana GT, Khamashta MA, Taylor JC: Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol. 1991, 85: 254-261.PubMedCentralCrossRefPubMed

30.

Carvalho D, Savage CO, Black CM, Pearson JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996, 97: 111-119.PubMedCentralCrossRefPubMed

31.

Bordron A, Dueymes M, Levy Y, Jamin C, Leroy JP, Piette JC, Shoenfeld Y, Youinou PY: The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis. J Clin Invest. 1998, 101: 2029-2035.PubMedCentralCrossRefPubMed

32.

Del Papa N, Guidali L, Spatola L, Bonara P, Borghi MO, Tincani A, Balestrieri G, Meroni PL: Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin Exp Rheumatol. 1995, 13: 179-185.PubMed

33.

Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, Koike T, Balestrieri G, Tincani A, Hughes GR, Meroni PL: Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997, 40: 551-561.CrossRefPubMed

34.

Papa ND, Raschi E, Moroni G, Panzeri P, Borghi MO, Ponticelli C, Tincani A, Balestrieri G, Meroni PL: Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus. 1999, 8: 423-429.CrossRefPubMed

35.

Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 1993, 92: 412-418.PubMedCentralCrossRefPubMed

36.

Belmont HM, Buyon J, Giorno R, Abramson S: Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 1994, 37: 376-383.CrossRefPubMed

37.

Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W: Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol. 1993, 20: 809-814.PubMed

38.

Song J, Park YB, Lee WK, Lee KH, Lee SK: Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int. 2000, 20: 1-7. 10.1007/s002960000060.CrossRefPubMed

39.

Meroni PL, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E, Cavazzana I, Pellegrini S, Salmaggi A: Endothelium and the brain in CNS lupus. Lupus. 2003, 12: 919-928. 10.1191/0961203303lu503oa.CrossRefPubMed

40.

Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GR: Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol. 1984, 2: 47-51.PubMed

41.

Asherson RA, Khamashta MA, Gil A, Vazquez JJ, Chan O, Baguley E, Hughes GR: Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med. 1989, 86: 391-399. 10.1016/0002-9343(89)90335-5.CrossRefPubMed

42.

Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR: Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994, 37: 568-571.CrossRefPubMed

43.

Sanna G, Bertolaccini ML, Cuadrado MJ, Laing H, Khamashta MA, Mathieu A, Hughes GR: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003, 30: 985-992.PubMed

44.

Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Pini C, Palladini G, Valesini G: Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun. 1998, 11: 425-429. 10.1006/jaut.1998.0214.CrossRefPubMed

45.

Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G, Valesini G: Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol. 1999, 115: 214-219. 10.1046/j.1365-2249.1999.00770.x.PubMedCentralCrossRefPubMed

46.

Chan TM, Yu PM, Tsang KL, Cheng IK: Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations. Clin Exp Immunol. 1995, 100: 506-513.PubMedCentralCrossRefPubMed

47.

Chan TM, Cheng IK: Identification of endothelial cell membrane proteins that bind anti-DNA antibodies from patients with systemic lupus erythematosus by direct or indirect mechanisms. J Autoimmun. 1997, 10: 433-439. 10.1006/jaut.1997.9998.CrossRefPubMed

48.

Moscato S, Pratesi F, Bongiorni F, Scavuzzo MC, Chimenti D, Bombardieri S, Migliorini P: Endothelial cell binding by systemic lupus antibodies: functional properties and relationship with anti-DNA activity. J Autoimmun. 2002, 18: 231-238. 10.1006/jaut.2002.0583.CrossRefPubMed

49.

Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB: Ribosomal P autoantibodies in SLE. Arthritis Rheum. 1996, 39: 1833-1839.CrossRefPubMed

50.

Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, De Angelis V, Cesarotti M, Piccirilli M, Quartesan R, Moretti P, Cantoni C, Franceschini F, Cavazzana I, Origgi L, Vanoli M, Bozzolo E, Ferrario L, Padovani A, Gambini O, Vanzulli L, Croce D, Bombardieri S: Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology. 2002, 41: 1357-1366. 10.1093/rheumatology/41.12.1357.CrossRefPubMed

51.

Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, Mimori A, Takeda A, Minota S, Kano S: Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1995, 22: 1681-1687.PubMed

52.

Frampton G, Moriya S, Pearson JD, Isenberg DA, Ward FJ, Smith TA, Panayiotou A, Staines NA, Murphy JJ: Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. Rheumatology. 2000, 39: 1114-1120. 10.1093/rheumatology/39.10.1114.CrossRefPubMed

53.

Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, Ahmed A, Cauli A, Montaldo C, Passiu G, Peter JB, Shoenfeld Y, Mathieu A: Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000, 9: 573-583. 10.1191/096120300678828695.CrossRefPubMed

54.

Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M, Ishihara T: Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int. 1998, 48: 332-340.CrossRefPubMed

55.

Tanaka J, Nakamura K, Takeda M, Tada K, Suzuki H, Morita H, Okado T, Hariguchi S, Nishimura T: Enzyme-linked immunosorbent assay for human autoantibody to glial fibrillary acidic protein: higher titer of the antibody is detected in serum of patients with Alzheimer's disease. Acta Neurol Scand. 1989, 80: 554-560.CrossRefPubMed

56.

Newcombe J, Gahan S, Cuzner ML: Serum antibodies against central nervous system proteins in human demyelinating disease. Clin Exp Immunol. 1985, 59: 383-390.PubMedCentralPubMed

57.

Trysberg E, Nylen K, Rosengren LE, Tarkowski A: Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003, 48: 2881-2887. 10.1002/art.11279.CrossRefPubMed

58.

Utset TO, Golden M, Siberry G, Kiri N, Crum RM, Petri M: Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjogren's syndrome. J Rheumatol. 1994, 21: 2039-2045.PubMed

Title: Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies
Authors: Fabrizio Conti
Cristiano Alessandri
Daniela Bompane
Michele Bombardieri
Francesca Romana Spinelli
Anna Carlotta Rusconi
Guido Valesini
Publication date: 01-08-2004
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 4/2004
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1198

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2004

What should be the core outcomes in chronic pain clinical trials?

Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus

Diosgenin, a plant steroid, induces apoptosis in human rheumatoid arthritis synoviocytes with cyclooxygenase-2 overexpression

CD25brightCD4+regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease

Ageing, autoimmunity and arthritis: Senescence of the B cell compartment – implications for humoral immunity

Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page